NCT06265272Recruiting
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
Technical Development and Clinical Validation of a Comprehensive One-stop Shop Assessment of the Cirrhotic Liver With [68Ga]Ga-PSMA-11 PET/MRI
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients * Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation. * Ga-PSMA PET/MRI may allow noninvasive and reproducible quantitation of portal venous hypertension and predict its evolution, as well as response to treatments * Ga-PSMA PET/MRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 45 (estimated)
- First submitted
- 2 Feb 2024
- Start date
- 10 Dec 2023
- Primary completion date
- 19 Dec 2028
- Lead sponsor
- Massachusetts General Hospital
- NCT number
- NCT06265272
What you commit to
- Study type: Observational
- Planned participants: 45
- From 10 Dec 2023 to the primary completion date, 19 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cumulative radiation exposure for research studies during the prior 12 months, combined with the exposure from this study, \> 50 mSv
Other illness
- Any contraindication to gadolinium-based contrast agent, including allergy to gadolinium, as in attached screening forms.
Other
- Any contraindication to PET, as in attached screening form
- Any contraindication to MRI, as in attached screening form
- Pregnancy
- Breast feeding.
- Inability to fit in the scanner: weight \> 300 lbs or BMI \> 33
Who the study is looking for
- Liver cirrhosis as diagnosed by imaging and/or clinical data, including pathology
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School Coordinator of this site? Confirm its status | Charlestown | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.